Lupagen

Executive Summary

Lupagen is a U.S.-based medical device and services company founded in 2015, focused on simplifying and reducing the cost of cell and gene therapy administration. Its proprietary Xynvivo™ System is an extracorporeal platform that enables bedside, closed-loop processing—including cell collection, vector binding, and reinfusion—eliminating the need for complex central manufacturing and cold-chain logistics. By addressing key bottlenecks in development, manufacturing, and market access, Lupagen aims to lower the barrier to adoption for advanced therapies. The company is currently in the pre-clinical stage, with its technology positioned as a full-service solution for biopharma partners seeking to streamline therapy delivery. Lupagen's value proposition centers on its ability to make cell and gene therapies more accessible and scalable by bringing critical steps to the patient's bedside. This approach could significantly reduce treatment costs and expand the addressable patient population. As a private company with limited public information, Lupagen's progress relies on securing partnerships, funding, and regulatory milestones. The upcoming catalysts are expected to demonstrate the platform's feasibility and commercial potential, though execution risk remains high at this early stage.

Upcoming Catalysts (preview)

• Q3 2026Partnership Announcement with a Cell Therapy Developer60% success
• 2027Initiation of First-in-Human Clinical Trial for Xynvivo System40% success
• H2 2026Series A Funding Round Closure70% success